Otsuka jumps into the US biotech M&A game, bagging Visterra in $430M buyout
After raising a bit more than $117 million from some blue chip backers like the Bill & Melinda Gates Foundation, Vertex and Flagship, Waltham, MA-based Visterra has agreed to a $430 million buyout deal, joining Japan’s Otsuka as a subsidiary.
Visterra and its antibody platform — all about binding to epitopes — will now remain in operation under Otsuka, which joins a growing group of Japanese companies with a big presence in the Boston hub.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
